Premium
A randomized, placebo‐controlled, double‐blind study of hysteroscopic‐guided pertubal diluted bupivacaine infusion for endometriosis‐associated chronic pelvic pain
Author(s) -
Shokeir Tarek,
Mousa Sherif
Publication year - 2015
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2015.03.043
Subject(s) - medicine , bupivacaine , visual analogue scale , pelvic pain , placebo , endometriosis , anesthesia , randomized controlled trial , randomization , patient satisfaction , placebo controlled study , surgery , double blind , gynecology , alternative medicine , pathology
Objective To assess the effectiveness of hysteroscopic‐guided pertubal diluted bupivacaine infusion for endometriosis‐associated chronic pelvic pain (CPP). Methods Between June 2010 and July 2013, a randomized, placebo‐controlled, double‐blind study was undertaken at Mansoura University Hospital, Mansoura, Egypt. Patients meeting inclusion criteria (laparoscopically confirmed endometriosis, patent fallopian tubes, ≥ 6 months CPP, pain score on visual analogue scale [VAS] > 5) were randomly assigned using a computer‐generated randomization sequence to receive either office hysteroscopic‐guided pertubal diluted bupivacaine infusion (0.25%) or placebo. Response to treatment was assessed using subjective data for scores on VAS and a monthly verbal rating scale (VRS monthly ) at baseline and at 1, 2, and 3 months of follow‐up. Additionally, women completed a questionnaire to evaluate the overall satisfaction at 3 months. Results Thirty patients were assigned to each group. In the bupivacaine group, VAS and VRS monthly scores were significantly lower at 1, 2, and 3 months than at baseline ( P < 0.05 for all). Additionally, scores were significantly lower in the bupivacaine group than in the placebo group at 1, 2, and 3 months ( P < 0.05 for all). At 3 months, 22 (73%) women in the bupivacaine group expressed satisfaction, compared with 2 (7%) in the placebo group ( P = 0.18). Conclusion Office pertubal hysteroscopic‐guided diluted bupivacaine infusion could be used to manage endometriosis‐associated CPP for at least 3 months. AEARCTR‐0000573